Market Overview

Clinical Cardiology Publishes Study Demonstrating Simple Blood Test from Prevencio Accurately Detects Cardiovascular Disease


Multi-protein diagnostic test with 98 percent accuracy published in
official journal of the American Society for Preventive Cardiology

Prevencio, Inc., announces the publication of data that demonstrates a
simple new blood test accurately diagnoses significant Peripheral Artery
Disease (PAD), a circulatory problem in which plaque-narrowed arteries
reduce blood flow to a patient's limbs and kidneys. If left untreated,
PAD can lead to clogged arteries and increase the risk of a major
cardiac event or amputation. Researchers believe the data, published in Clinical
, could lead to the use of this test as a gatekeeper to
imaging or invasive testing, thus reducing cost and exposures to
potentially harmful intravenous contrast and/or ionizing radiation.

In the study, Massachusetts General Hospital and Prevencio researchers
developed and validated a multi-protein blood test, HARTTM
PAD, that identifies the presence of PAD and predicts the need for a
future medical intervention. Principal Investigator James L. Januzzi,
MD, is a practicing cardiologist at Massachusetts General Hospital and
Professor of Medicine at Harvard Medical School.

Januzzi and a team of researchers tested 355 patients referred for
diagnostic peripheral angiography to Massachusetts General Hospital.
When divided into low-risk and high-risk categories, the HART PAD test
predicted with 98 percent accuracy to exclude obstruction of the
peripheral arteries. Additionally, the test predicted with 86 percent
accuracy to identify obstruction of the peripheral arteries.

"This blood test may allow for the diagnosis and treatment of many more
patients with PAD," said Januzzi. "As well as giving physicians the
opportunity to provide patients with more appropriate care, we believe
the test could also benefit clinical trials by saving time and thereby
lowering overall trial costs."

PAD affects more than 202 million people globally and is often
underdiagnosed and undertreated until the disease has reached its
advanced stages. In addition to the HART PAD test, Prevencio is
developing a multi-protein blood test, HART AMP, to specifically
identify a patient's risk for amputation.

"We are pleased to have our third publication validating the high
accuracy of our HART tests which have the potential to improve treatment
for millions of cardiovascular patients," said Rhonda Rhyne, Prevencio's
Chief Executive Officer. "This could not have been accomplished without
our collaboration with Dr. Januzzi and his researchers and Myriad RBM.
It is also highly rewarding to work on our HART biomarker blood tests
with pharmaceutical companies to test drug efficacy, improve drug
development, and decrease clinical trial expenses."

Powered by AI, Prevencio is revolutionizing blood tests for
cardiovascular disease. Employing this novel approach, the company has
produced five blood tests to-date that significantly improve diagnoses
for a variety of heart and blood vessel-related complications.

These tests are:

1. HART CADTM – obstructive coronary artery disease diagnosis

2. HART CVETM – 1-year risk of heart attack, stroke or
cardiac death

3. HART PADTM – peripheral artery disease diagnosis

4. HART ASTM – aortic valve stenosis diagnosis

5. HART AMPTM – risk of amputation

HART test results have been presented at leading cardiovascular
meetings—(European Society of Cardiology Congress Scientific Sessions –
2016, American College of Cardiology Scientific Sessions – 2017,
American Heart Association Scientific Sessions – 2017, American College
of Cardiology Scientific Sessions – 2018, American Diabetes Association
Scientific Sessions – 2018) and published in top-tier cardiology
journals (Journal of American College of Cardiology – March 2017, American
Journal of Cardiology
– July 2017, and Clinical Cardiology,
June 2018).

About Prevencio, Inc.:

Prevencio's value proposition is "Preventing the Preventable" — That is,
preventing unnecessary procedures and related side effects, as well as
improving patient outcomes and clinical trials through more accurate
blood tests for Cardiovascular Disease conditions. Prevencio utilizes
Machine Learning (Artificial Intelligence) + Multi-Proteomic Biomarkers
+ Proprietary Algorithms to deliver cardiovascular diagnostic &
prognostic tests that are significantly more accurate than
standard-of-care stress tests, individual biomarkers, genetic markers
and clinical risk scores. The company is headquartered in Kirkland,
Washington. For additional information, visit
Prevencio—Preventing the Preventable.™

Forward-Looking (Safe Harbor) Statement:

Except for historical and factual information contained herein, this
press release contains forward-looking statements, such as market need,
acceptance, size, potential, and penetration rates, the accuracy of
which is necessarily subject to uncertainties and risks including the
Company's sole dependence on HART technology and various uncertainties
characteristic of development-stage companies. The Company does not
undertake to update the disclosures contained in this press release.

View Comments and Join the Discussion!